188 related articles for article (PubMed ID: 19029962)
1. Delay in B-lymphocyte recovery and function following rituximab for EBV-associated lymphoproliferative disease early post-allogeneic hematopoietic SCT.
Masjosthusmann K; Ehlert K; Eing BR; Roth J; Koehler G; Juergens H; Fruehwald M; Groll AH
Bone Marrow Transplant; 2009 May; 43(9):679-84. PubMed ID: 19029962
[TBL] [Abstract][Full Text] [Related]
2. Impaired B-cell reconstitution in lymphoma patients undergoing allogeneic HSCT: an effect of pretreatment with rituximab?
Buser A; Stern M; Arber C; Medinger M; Halter J; Rovo A; Favre G; Lohri A; Tichelli A; Gratwohl A
Bone Marrow Transplant; 2008 Oct; 42(7):483-7. PubMed ID: 18695668
[TBL] [Abstract][Full Text] [Related]
3. Viral-load and B-lymphocyte monitoring of EBV reactivation after allogeneic hemopoietic SCT in children.
Faraci M; Caviglia I; Morreale G; Lanino E; Cuzzubbo D; Giardino S; Di Marco E; Cirillo C; Scuderi F; Dallorso S; Terranova P; Moroni C; Castagnola E
Bone Marrow Transplant; 2010 Jun; 45(6):1052-5. PubMed ID: 19855442
[TBL] [Abstract][Full Text] [Related]
4. Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation.
McGuirk JP; Seropian S; Howe G; Smith B; Stoddart L; Cooper DL
Bone Marrow Transplant; 1999 Dec; 24(11):1253-8. PubMed ID: 10642818
[TBL] [Abstract][Full Text] [Related]
5. Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation.
Gruhn B; Meerbach A; Häfer R; Zell R; Wutzler P; Zintl F
Bone Marrow Transplant; 2003 Jun; 31(11):1023-5. PubMed ID: 12774054
[TBL] [Abstract][Full Text] [Related]
6. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease.
Meerbach A; Wutzler P; Häfer R; Zintl F; Gruhn B
J Med Virol; 2008 Mar; 80(3):441-54. PubMed ID: 18205222
[TBL] [Abstract][Full Text] [Related]
7. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
Kinch A; Oberg G; Arvidson J; Falk KI; Linde A; Pauksens K
Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054
[TBL] [Abstract][Full Text] [Related]
8. Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute.
Hou HA; Yao M; Tang JL; Chen YK; Ko BS; Huang SY; Tien HF; Chang HH; Lu MY; Lin TT; Lin KH; Hsiao CH; Lin CW; Chen YC
Bone Marrow Transplant; 2009 Feb; 43(4):315-21. PubMed ID: 18836488
[TBL] [Abstract][Full Text] [Related]
9. The real-time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation.
Cesaro S; Murrone A; Mengoli C; Pillon M; Biasolo MA; Calore E; Tridello G; Varotto S; Alaggio R; Zanesco L; Palù G; Messina C
Br J Haematol; 2005 Jan; 128(2):224-33. PubMed ID: 15638858
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan.
Sato E; Ohga S; Kuroda H; Yoshiba F; Nishimura M; Nagasawa M; Inoue M; Kawa K
Am J Hematol; 2008 Sep; 83(9):721-7. PubMed ID: 18626884
[TBL] [Abstract][Full Text] [Related]
11. EBV lymphoproliferative disease of host origin after haploidentical stem cell transplantation.
Kasow KA; Leung W; Horwitz EM; Woodard P; Handgretinger R; Hale GA
Pediatr Blood Cancer; 2007 Nov; 49(6):869-72. PubMed ID: 16421900
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.
Meijer E; Cornelissen JJ
Curr Opin Hematol; 2008 Nov; 15(6):576-85. PubMed ID: 18832928
[TBL] [Abstract][Full Text] [Related]
13. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation.
Ahmad I; Cau NV; Kwan J; Maaroufi Y; Meuleman N; Aoun M; Lewalle P; Martiat P; Crokaert F; Bron D
Transplantation; 2009 Apr; 87(8):1240-5. PubMed ID: 19384173
[TBL] [Abstract][Full Text] [Related]
14. [EBV quantification in children after allogeneic hematopoietic stem cell transplantation].
Hubácek P; Cinek O; Kulich M; Zajac M; Keslová P; Formánková R; Starý J; Sedlácek P
Cas Lek Cesk; 2006; 145(4):301-6. PubMed ID: 16639931
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic stem cell transplantation conditioning with use of rituximab in EBV related lymphoproliferative disorders.
Shamriz O; Vilk SR; Wolf DG; Ta-Shma A; Averbuch D; Weintraub M; Stepensky P
Clin Immunol; 2014 Apr; 151(2):79-83. PubMed ID: 24584040
[TBL] [Abstract][Full Text] [Related]
16. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies.
García-Suárez J; de Miguel D; Krsnik I; Bañas H; Arribas I; Burgaleta C
Am J Hematol; 2005 Dec; 80(4):271-81. PubMed ID: 16315252
[TBL] [Abstract][Full Text] [Related]
17. Post-transplant EBV-related lymphoproliferative disorder complicating umbilical cord blood transplantation in patients of adrenoleukodystrophy.
Cheng FW; Lee V; To KF; Chan KC; Shing MK; Li CK
Pediatr Blood Cancer; 2009 Dec; 53(7):1329-31. PubMed ID: 19591223
[TBL] [Abstract][Full Text] [Related]
18. Rituximab for lymphoproliferative disease prior to haematopoietic stem cell transplantation for X-linked severe combined immunodeficiency.
Trahair TN; Wainstein B; Manton N; Bourne AJ; Ziegler JB; Rice M; Russell SJ
Pediatr Blood Cancer; 2008 Feb; 50(2):366-9. PubMed ID: 16732583
[TBL] [Abstract][Full Text] [Related]
19. Increased infection rate after preemptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem-cell transplantation.
Petropoulou AD; Porcher R; Peffault de Latour R; Xhaard A; Weisdorf D; Ribaud P; Rodriguez-Otero P; Agbalika F; Talbot A; Toubert A; Moins-Teisserenc H; Carmagnat M; Socié G; Robin M
Transplantation; 2012 Oct; 94(8):879-83. PubMed ID: 23001354
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic hematopoietic stem cell transplantation recipients have defects of both switched and igm memory B cells.
D'Orsogna LJ; Wright MP; Krueger RG; McKinnon EJ; Buffery SI; Witt CS; Staples N; Loh R; Cannell PK; Christiansen FT; French MA
Biol Blood Marrow Transplant; 2009 Jul; 15(7):795-803. PubMed ID: 19539210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
